Phase 1 clinical trial of PT217 for n... - Fight Prostate Ca...

Fight Prostate Cancer

3,028 members1,499 posts

Phase 1 clinical trial of PT217 for neuroendocrine prostate cancer

Maxone73 profile image
0 Replies

PT217 is a novel bispecific antibody (bsAb) designed to block both DLL3 and CD47, two pathways important in cancer growth and immune evasion. Developed by Phanes Therapeutics, it is aimed at aggressive malignancies such as small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC). The FDA has granted PT217 its second Fast Track designation, specifically for NEPC, underscoring an urgent need for new treatments in this field.

This recognition follows an earlier Fast Track designation for extensive-stage SCLC. The drug also holds orphan designations for both SCLC and neuroendocrine carcinoma. Currently, PT217 is under investigation in the SKYBRIDGE study (Phase I/II) in the US and a separate Phase I trial in China. Researchers are measuring safety, tolerability, and initial effectiveness in advanced or refractory cancers that express DLL3. Phanes Therapeutics has additionally entered a supply agreement to evaluate PT217 in combination with the anti-PD-L1 medication atezolizumab.

The FDA’s latest decision highlights PT217’s promise as a novel therapy for patients facing difficult-to-treat forms of prostate cancer.

prostatewarriors.com/2025/0...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Update on Prostate Cancer Vaccines from Previous Posts done 1 year ago

Hello FPC forum, About a year ago, I posted a series of articles on prostate cancer vaccine...
NPfisherman profile image

Great update: 67Cu-SAR-bisPSMA gets fast tracked by FDA

And it looks like it is way more reliable than 177Lu... The FDA has granted Fast Track Designation...
Maxone73 profile image

Phase 1 recruiting: QXL138AM, for CD138 expressing tumors

Another one I almost missed... CD138 is expressed in advanced and aggressive prostate cancers,...
Maxone73 profile image

Warming Up the Cold: A New Hope for Immunotherapy in Prostate Cancer

Ok, Phase 1 data were encouraging, but the sample was small, only 35 patients. But 21% had a PSA...
Maxone73 profile image

Phase 3 ended: ECLIPSE trial of 177Lu-PSMA-I&T

A phase 3 clinical trial called ECLIPSE has shown that 177Lu-PSMA-I&T significantly extends the...
Maxone73 profile image